Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,915 shares of the biopharmaceutical company's stock after acquiring an additional 2,310 shares during the period. Treasurer of the State of North Carolina owned about 0.07% of Alnylam Pharmaceuticals worth $20,452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $577,941,000. Raymond James Financial Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $65,295,000. Jennison Associates LLC purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $61,160,000. Finally, Proficio Capital Partners LLC raised its stake in shares of Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock worth $45,570,000 after buying an additional 192,916 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director Phillip A. Sharp sold 11,250 shares of the business's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by corporate insiders.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded down $0.43 on Wednesday, hitting $230.50. The stock had a trading volume of 1,010,678 shares, compared to its average volume of 873,311. The company's 50 day moving average price is $251.53 and its 200 day moving average price is $257.83. The stock has a market cap of $29.98 billion, a price-to-earnings ratio of -106.22 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ALNY shares. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Finally, Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.